Press Release – Modra Pharmaceuticals

Modra Pharmaceuticals Announces U.S. Patent Issuance for ModraDoc006/r

...

Modra Pharmaceuticals Presents In-Depth Data Analysis from Lower Dose Cohort in Phase 2b Study of Oral Taxane ModraDoc006/r in mCRPC Patients at 2022 ASCO Annual Meeting

...

Modra Pharmaceuticals to Present New Phase 2b Data at the 2022 ASCO General Annual Meeting on ModraDoc006/r, a Boosted Oral Taxane for Patients with Metastatic Prostate Cancer

...

Modra Pharmaceuticals Presents Positive Phase IIb Results for ModraDoc006/r, a Boosted Oral Taxane for Patients with Metastatic Prostate Cancer, at 2022 ASCO GU Annual Meeting

...

Modra Pharmaceuticals Appoints Two New Supervisory Board Members Adding Significant Experience in Corporate and Clinical Development

Amsterdam, April 27, 2021 – Modra Pharmaceuticals (“Modra”) today announced the appointment of Hemanshu Shah, Ph.D., MBA and Klaus Sch...

Modra Pharmaceuticals Presents Preliminary Data from Phase IIb Trial of ModraDoc006/r in Metastatic Prostate Cancer at 2021 ASCO GU Annual Meeting

...

ModraDoc006/Ritonavir Offers Promising Therapeutic Option for mCRPC

11 February 2021 ModraDoc006/Ritonavir Offers Promising Therapeutic Option for mCRPC, Convenient Approach Amid COVID-19 Pandemic Article published in ...

Modra Pharmaceuticals Announces First Patients Treated in Phase IIb Metastatic Prostate Cancer Trial

14 august 2019 –Study will test efficacy and tolerability of novel docetaxel-based oral chemotherapeutic ModraDoc006/r– Amsterdam A...

Follow Us